Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Claims Must Be Written Narrowly, Federal Circuit Reaffirms In Ariad v. Lilly

This article was originally published in The Pink Sheet Daily

Executive Summary

Ruling in favor of Lilly, an en banc panel finds that the requirement that patent claims provide an adequate written description of an invention is separate from enabling someone to use the invention. 

You may also be interested in...



PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial

Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.

Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes

Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.

Lilly Laid Groundwork For Abbott's Defeat Of J&J's Patent Verdict On Humira

Abbott Laboratories had reason to thank Eli Lilly & Co. when the U.S. Court of Appeals for the Federal Circuit overturned a record $1.67-billion jury verdict that Abbott's Humira infringed a Johnson & Johnson patent.

Topics

Latest News
UsernamePublicRestriction

Register

PS070392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel